Cargando…

Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?

Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytoma predominantly affecting children and young adults. We performed comprehensive genomic characterization on a cohort of 67 patients with histologically defined PXA (n = 53, 79%) or anaplastic PXA (A‐PXA, n = 14, 21%), including copy number anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaubel, Rachael, Zschernack, Valentina, Tran, Quynh T., Jenkins, Sarah, Caron, Alissa, Milosevic, Dragana, Smadbeck, James, Vasmatzis, George, Kandels, Daniela, Gnekow, Astrid, Kramm, Christof, Jenkins, Robert, Kipp, Benjamin R., Rodriguez, Fausto J., Orr, Brent A., Pietsch, Torsten, Giannini, Caterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018001/
https://www.ncbi.nlm.nih.gov/pubmed/32619305
http://dx.doi.org/10.1111/bpa.12874
_version_ 1783674150831783936
author Vaubel, Rachael
Zschernack, Valentina
Tran, Quynh T.
Jenkins, Sarah
Caron, Alissa
Milosevic, Dragana
Smadbeck, James
Vasmatzis, George
Kandels, Daniela
Gnekow, Astrid
Kramm, Christof
Jenkins, Robert
Kipp, Benjamin R.
Rodriguez, Fausto J.
Orr, Brent A.
Pietsch, Torsten
Giannini, Caterina
author_facet Vaubel, Rachael
Zschernack, Valentina
Tran, Quynh T.
Jenkins, Sarah
Caron, Alissa
Milosevic, Dragana
Smadbeck, James
Vasmatzis, George
Kandels, Daniela
Gnekow, Astrid
Kramm, Christof
Jenkins, Robert
Kipp, Benjamin R.
Rodriguez, Fausto J.
Orr, Brent A.
Pietsch, Torsten
Giannini, Caterina
author_sort Vaubel, Rachael
collection PubMed
description Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytoma predominantly affecting children and young adults. We performed comprehensive genomic characterization on a cohort of 67 patients with histologically defined PXA (n = 53, 79%) or anaplastic PXA (A‐PXA, n = 14, 21%), including copy number analysis (ThermoFisher Oncoscan, n = 67), methylation profiling (Illumina EPIC array, n = 43) and targeted next generation sequencing (n = 32). The most frequent alterations were CDKN2A/B deletion (n = 63; 94%) and BRAF p.V600E (n = 51, 76.1%). In 7 BRAF p.V600 wild‐type cases, alternative driver alterations were identified involving BRAF, RAF1 and NF1. Downstream phosphorylation of ERK kinase was uniformly present. Additional pathogenic alterations were rare, with TERT, ATRX and TP53 mutations identified in a small number of tumors, predominantly A‐PXA. Methylation‐based classification of 46 cases utilizing a comprehensive reference tumor allowed assignment to the PXA methylation class in 40 cases. A minority grouped with the methylation classes of ganglioglioma or pilocytic astrocytoma (n = 2), anaplastic pilocytic astrocytoma (n = 2) or control tissues (n = 2). In 9 cases, tissue was available from matched primary and recurrent tumors, including 8 with anaplastic transformation. At recurrence, two tumors acquired TERT promoter mutations and the majority demonstrated additional non‐recurrent copy number alterations. Methylation class was preserved at recurrence. For 62 patients (92.5%), clinical follow‐up data were available (median follow‐up, 5.4 years). Overall survival was significantly different between PXA and A‐PXA (5‐year OS 80.8% vs. 47.6%; P = 0.0009) but not progression‐free survival (5‐year PFS 59.9% vs. 39.8%; P = 0.05). WHO grade remained a strong predictor of overall survival when limited to 38 cases defined as PXA by methylation‐based classification. Our data confirm the importance of WHO grading in histologically and epigenetically defined PXA. Methylation‐based classification may be helpful in cases with ambiguous morphology, but is largely confirmatory in PXA with well‐defined morphology.
format Online
Article
Text
id pubmed-8018001
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80180012021-09-03 Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it? Vaubel, Rachael Zschernack, Valentina Tran, Quynh T. Jenkins, Sarah Caron, Alissa Milosevic, Dragana Smadbeck, James Vasmatzis, George Kandels, Daniela Gnekow, Astrid Kramm, Christof Jenkins, Robert Kipp, Benjamin R. Rodriguez, Fausto J. Orr, Brent A. Pietsch, Torsten Giannini, Caterina Brain Pathol Research Articles Pleomorphic xanthoastrocytoma (PXA) is a rare astrocytoma predominantly affecting children and young adults. We performed comprehensive genomic characterization on a cohort of 67 patients with histologically defined PXA (n = 53, 79%) or anaplastic PXA (A‐PXA, n = 14, 21%), including copy number analysis (ThermoFisher Oncoscan, n = 67), methylation profiling (Illumina EPIC array, n = 43) and targeted next generation sequencing (n = 32). The most frequent alterations were CDKN2A/B deletion (n = 63; 94%) and BRAF p.V600E (n = 51, 76.1%). In 7 BRAF p.V600 wild‐type cases, alternative driver alterations were identified involving BRAF, RAF1 and NF1. Downstream phosphorylation of ERK kinase was uniformly present. Additional pathogenic alterations were rare, with TERT, ATRX and TP53 mutations identified in a small number of tumors, predominantly A‐PXA. Methylation‐based classification of 46 cases utilizing a comprehensive reference tumor allowed assignment to the PXA methylation class in 40 cases. A minority grouped with the methylation classes of ganglioglioma or pilocytic astrocytoma (n = 2), anaplastic pilocytic astrocytoma (n = 2) or control tissues (n = 2). In 9 cases, tissue was available from matched primary and recurrent tumors, including 8 with anaplastic transformation. At recurrence, two tumors acquired TERT promoter mutations and the majority demonstrated additional non‐recurrent copy number alterations. Methylation class was preserved at recurrence. For 62 patients (92.5%), clinical follow‐up data were available (median follow‐up, 5.4 years). Overall survival was significantly different between PXA and A‐PXA (5‐year OS 80.8% vs. 47.6%; P = 0.0009) but not progression‐free survival (5‐year PFS 59.9% vs. 39.8%; P = 0.05). WHO grade remained a strong predictor of overall survival when limited to 38 cases defined as PXA by methylation‐based classification. Our data confirm the importance of WHO grading in histologically and epigenetically defined PXA. Methylation‐based classification may be helpful in cases with ambiguous morphology, but is largely confirmatory in PXA with well‐defined morphology. John Wiley and Sons Inc. 2020-08-04 /pmc/articles/PMC8018001/ /pubmed/32619305 http://dx.doi.org/10.1111/bpa.12874 Text en © 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Vaubel, Rachael
Zschernack, Valentina
Tran, Quynh T.
Jenkins, Sarah
Caron, Alissa
Milosevic, Dragana
Smadbeck, James
Vasmatzis, George
Kandels, Daniela
Gnekow, Astrid
Kramm, Christof
Jenkins, Robert
Kipp, Benjamin R.
Rodriguez, Fausto J.
Orr, Brent A.
Pietsch, Torsten
Giannini, Caterina
Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?
title Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?
title_full Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?
title_fullStr Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?
title_full_unstemmed Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?
title_short Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?
title_sort biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018001/
https://www.ncbi.nlm.nih.gov/pubmed/32619305
http://dx.doi.org/10.1111/bpa.12874
work_keys_str_mv AT vaubelrachael biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT zschernackvalentina biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT tranquynht biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT jenkinssarah biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT caronalissa biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT milosevicdragana biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT smadbeckjames biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT vasmatzisgeorge biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT kandelsdaniela biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT gnekowastrid biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT krammchristof biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT jenkinsrobert biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT kippbenjaminr biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT rodriguezfaustoj biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT orrbrenta biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT pietschtorsten biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit
AT gianninicaterina biologyandgradingofpleomorphicxanthoastrocytomawhathavewelearnedaboutit